1Department of Neurology, CHA Bundang Medical Center, CHA University, Seongnam, Korea
2Institute of Neurogenetics, University of Lübeck and University Hospital of Schleswig-Holstein, Lübeck, Germany
3Advanced Center for Parkinson’s Disease Research, Harvard Medical School, Brigham and Women’s Hospital, Boston, MA, USA
4Precision Neurology Program, Harvard Medical School, Brigham and Women’s Hospital, Boston, MA, USA
5Department of Neurology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
Copyright © 2023 The Korean Movement Disorder Society
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Conflicts of Interest
The authors have no financial conflicts of interest. Christine Klein is medical advisor to Centogene and Retromer Therapeutics and received Speakers’ honoraria from Desitin and Bial, however these do not affect the content of the manuscript.
Funding Statement
This research was supported by the Basic Science Research Program through the National Research Foundation of Korea, funded by the Ministry of Science and ICT (2021R1C1C1010753). This study was also supported by the Asan Institute for Life Sciences, Asan Medical Center, Seoul, Republic of Korea (grant number: 2022IT0012).
Author Contributions
Conceptualization: Young Eun Huh, Christine Klein, Sun Ju Chung. Funding acquisition: Young Eun Huh. Supervision: Christine Klein, Sun Ju Chung. Visualization: Young Eun Huh, Clemens R. Scherzer. Writing—original draft: Young Eun Huh. Writing—review & editing: all authors.
PD, Parkinson’s disease; GBA1, glucosylceramidase beta 1; GBA1-PD, Parkinson’s disease patients with a GBA1 mutation; idiopathic PD, Parkinson’s disease patients without GBA1 mutation; HR, hazard ratio; ns, not significant; HY, Hoehn and Yahr; REM, rapid eye movement; DBS, deep brain stimulation; LEDD, levodopa equivalent daily dosage; QOL, quality of life.
Comments on this article